Storia in 3 fonti

What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.

Raccontata da

economictimes.indiatimes.com

benzinga.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo5 g fa

What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.

originale

economictimes.indiatimes.com5 g fa

GSK's Jemperli meets main goal in mid-stage rectal cancer trial

GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for this cancer can lead to significant…

Leggi questa versione → originale

Timeline cronologica

lunedì 13 luglio 2026·economictimes.indiatimes.com
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for…
lunedì 13 luglio 2026·benzinga.com
What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)
GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.

What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

Confronto fonti

What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

GSK's Jemperli meets main goal in mid-stage rectal cancer trial

Timeline cronologica

GSK's Jemperli meets main goal in mid-stage rectal cancer trial

What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)

GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win

GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win